THE ELITE UNIVERSAL TEST
BANK: WOMEN’S HEALTH
PRIMARY CARE (5TH ED.)
PART 0: THE NAVIGATOR
● Tier 1 (Questions 1–28): Foundational Syntax & Application. Testing "Hard Deck"
definitions, core formulas, and primary theories (e.g., HRSA 2026 guidelines,
PALM-COEIN criteria, PREVENT equation thresholds).
● Tier 2 (Questions 29–58): Complex Application & Simulation. "Situation X occurs.
Variable Y changes. What is the MOST LOGICAL outcome or immediate action?" (e.g.,
protocol pivots during Bicillin shortages, mid-course HRT adjustments).
● Tier 3 (Questions 59–88): Grandmaster Synthesis. Paragraph-long, high-stakes
scenarios requiring the synthesis of multiple, competing concepts (e.g., managing AUB in
anticoagulated patients, treating STIs in gravid populations).
PART I: THE PRIMER
This document forges elite clinical practitioners by replacing rote memorization with surgical
diagnostic precision. Mastering this specific test bank translates directly to superior patient
outcomes, diagnostic accuracy, and total command of current global women's health protocols,
ensuring high-level clinical and analytical competence.
● The PALM-COEIN Axiom: Always separate structural (PALM: Polyp, Adenomyosis,
Leiomyoma, Malignancy) from non-structural (COEIN) causes of Abnormal Uterine
Bleeding (AUB). Endometrial biopsy is absolute in women >45 or those <45 with
unopposed estrogen exposure.
● The PREVENT (2024-2026) Axiom: Cardiovascular risk assessment now encompasses
ages 30-79, removes race, adds Heart Failure (HF) to ASCVD, incorporates eGFR/BMI,
and utilizes a 7.5% 10-year risk threshold for initiating statins or antihypertensives.
● The Cervical Cancer (HRSA 2026) Axiom: Patient self-collection for primary hrHPV
testing is now an approved standard for average-risk women aged 30–65 (every 5 years).
Co-testing is explicitly forbidden under age 30.
● The Antimicrobial Stewardship Axiom: During the 2025/2026 Bicillin L-A shortage,
imported Lentocilin or remaining Bicillin is reserved strictly for pregnant patients with
syphilis; non-pregnant adults default to Doxycycline.
● The Menopause (NAMS 2025) Axiom: Hormone Therapy (HT) does not need to be
routinely discontinued at age 65. Prescribe FDA-approved formulations based on
individualized VMS/GSM symptom burden and strictly avoid compounded bioidentical
hormones.
,Guideline Entity 2025/2026 Key Update Clinical Application Source
/ Threshold Focus
AHA/ACC PREVENT Equations Threshold for primary
intervention lowered to
7.5% 10-year CVD risk.
HRSA/USPSTF Cervical Screening Approves self-collected
vaginal samples for
hrHPV in women
30-65.
CDC Doxy-PEP 200mg doxycycline
within 72 hours for
high-risk STI
prevention.
ACOG Fetal Monitoring No routine oxygen for
Category II/III if mother
is normoxic.
USPSTF Breast Screening Biennial mammography
required starting at age
40, up to age 74.
PART II: THE ELITE TEST BANK
Q1: A 32-year-old average-risk patient requests cervical cancer screening. Based on the 2026
HRSA Women's Preventive Services Guidelines, which action is the FIRST line
recommendation? A) Perform cytology alone, as she is under age 35 B) Offer patient-collected
primary hrHPV testing C) Perform concurrent cytology and pelvic ultrasound D) Defer screening
until age 35 if prior cytology was normal
● The Answer: B (Offer patient-collected primary hrHPV testing)
● Distractor Analysis:
○ A is incorrect: Cytology alone is reserved for ages 21–29; at 32, hrHPV testing is
preferred.
○ C is incorrect: Ultrasound is not a screening modality for cervical cancer.
○ D is incorrect: Screening intervals are 3 years (cytology) or 5 years (hrHPV);
deferring to 35 violates the 5-year interval.
The Mentor's Analysis: HRSA 2026 protocols authorize self-collected hrHPV testing for women
30–65, fundamentally shifting primary care workflows to empower patient autonomy.
Professional/Academic Intuition: Empower 30-65-year-old patients with hrHPV
self-collection to maximize screening compliance.
Q2: A 24-year-old patient presents for an annual exam. Based on the HRSA 2026 Guidelines,
which cervical screening strategy is MOST APPROPRIATE? A) Co-testing (Cytology + hrHPV)
B) Primary hrHPV testing C) Cervical cytology alone D) Patient-collected hrHPV swab
● The Answer: C (Cervical cytology alone)
● Distractor Analysis:
○ A is incorrect: Co-testing is explicitly not recommended for women under 30.
○ B is incorrect: Primary hrHPV is reserved for women 30 and older.
○ D is incorrect: Self-collection applies only to the hrHPV test, which is
contraindicated for her age bracket.
The Mentor's Analysis: High-risk HPV infections are highly prevalent but transient in women
under 30. Testing for HPV in this cohort leads to unnecessary colposcopies.
,Professional/Academic Intuition: Never order HPV co-testing for a patient under 30 years
old.
Q3: A 47-year-old female presents with heavy menstrual bleeding. Based on the PALM-COEIN
framework, what is the IMMEDIATELY required diagnostic step? A) Prescribe a levonorgestrel
IUD B) Order an endometrial biopsy C) Measure endometrial thickness via ultrasound D) Initiate
a GnRH antagonist
● The Answer: B (Order an endometrial biopsy)
● Distractor Analysis:
○ A is incorrect: While the LNG-IUD treats AUB, ruling out malignancy is mandatory
first.
○ C is incorrect: Ultrasound thickness cannot reliably rule out malignancy in
premenopausal women.
○ D is incorrect: GnRH antagonists treat fibroids (AUB-L), but the "M" (Malignancy)
must be evaluated first.
The Mentor's Analysis: Age >45 with AUB mandates an automatic rule-out of endometrial
hyperplasia/malignancy per ACOG 2012 and NICE 2018 guidelines. Professional/Academic
Intuition: In AUB, tissue is the issue; biopsy anyone over 45 before initiating suppression.
Q4: A 31-year-old with a BMI of 36 and a history of PCOS reports irregular, heavy menses.
Based on AUB guidelines, what is the MOST ACCURATE initial action? A) Endometrial biopsy
B) Reassurance and weight loss counseling C) Transvaginal ultrasound to measure stripe
thickness D) Immediate hysterectomy
● The Answer: A (Endometrial biopsy)
● Distractor Analysis:
○ B is incorrect: Fails to address the immediate risk of endometrial hyperplasia
caused by unopposed estrogen.
○ C is incorrect: Ultrasound is not the primary diagnostic tool to rule out cancer in
anovulatory AUB.
○ D is incorrect: Hysterectomy is a radical endpoint, not an initial diagnostic step.
The Mentor's Analysis: Women <45 with unopposed estrogen exposure (PCOS, obesity) are at
high risk for endometrial cancer and bypass the standard age threshold for biopsy.
Professional/Academic Intuition: Unopposed estrogen environments demand an
endometrial biopsy regardless of the patient's age.
Q5: A 66-year-old woman requests cardiovascular risk assessment. Based on the 2024-2026
AHA PREVENT equations, which variable is EXPLICITLY excluded from the calculation? A)
Estimated Glomerular Filtration Rate (eGFR) B) Body Mass Index (BMI) C) Patient Race D)
Heart Failure risk
● The Answer: C (Patient Race)
● Distractor Analysis:
○ A is incorrect: eGFR is a newly integrated core variable in the CKM framework.
○ B is incorrect: BMI is now included in the base PREVENT model.
○ D is incorrect: Heart Failure (HF) is now predicted alongside ASCVD to calculate
total CVD.
The Mentor's Analysis: The AHA removed race to treat it as a social, rather than biological,
construct, while adding renal and metabolic metrics. Professional/Academic Intuition: Use the
PREVENT equations to evaluate Cardiovascular-Kidney-Metabolic (CKM) syndrome
holistically, ignoring race.
Q6: A 35-year-old male-to-female (MTF) transgender patient requests routine primary care.
Based on WPATH SOC8, which screening is MOST APPROPRIATE if the patient has not
, undergone gender-affirming surgery? A) Discontinue all prostate screenings permanently B)
Defer breast cancer screening until age 65 C) Routine prostate screening based on native
anatomical guidelines D) Routine cervical cytology
● The Answer: C (Routine prostate screening based on native anatomical guidelines)
● Distractor Analysis:
○ A is incorrect: The prostate is retained during standard vaginoplasty and remains at
risk.
○ B is incorrect: Estrogen exposure alters breast cancer risk; standard screening
protocols apply based on duration of hormone use.
○ D is incorrect: MTF patients do not possess a cervix.
The Mentor's Analysis: Gender-affirming care requires screening the anatomy present,
regardless of the patient's gender identity. Professional/Academic Intuition: Screen the organs
that are physically present; anatomy dictates preventative care protocols.
Q7: A 65-year-old female undergoes a DXA scan yielding a T-score of -2.6 at the femoral neck.
Based on ACP/ACOG 2025 guidelines, which is the FIRST-line pharmacologic intervention? A)
Denosumab B) Oral Bisphosphonates C) Teriparatide D) Estrogen replacement therapy
● The Answer: B (Oral Bisphosphonates)
● Distractor Analysis:
○ A is incorrect: Denosumab was shifted to second-line due to rebound fracture risks
upon discontinuation.
○ C is incorrect: Anabolic agents are reserved for very high-risk patients with severe,
existing fractures.
○ D is incorrect: Estrogen prevents bone loss but is not first-line treatment for
diagnosed osteoporosis.
The Mentor's Analysis: Bisphosphonates remain the anchor of osteoporosis management due
to proven fracture protection, safety, and lack of rebound effect. Professional/Academic Intuition:
All standard osteoporosis treatment pathways begin with bisphosphonates.
Q8: A 24-year-old non-pregnant female is diagnosed with primary syphilis during the 2026
Bicillin L-A shortage. Based on CDC protocols, which action is MOST ACCURATE? A)
Administer IV Ceftriaxone immediately B) Utilize imported Lentocilin C) Prescribe Doxycycline
100 mg orally twice daily for 14 days D) Prioritize the remaining clinic stock of Bicillin L-A for her
● The Answer: C (Prescribe Doxycycline 100 mg orally twice daily for 14 days)
● Distractor Analysis:
○ A is incorrect: Ceftriaxone is second-line and not the preferred alternative for
primary syphilis.
○ B is incorrect: Lentocilin (import) is strictly prioritized for pregnant patients.
○ D is incorrect: Bicillin stocks must be hoarded exclusively for pregnant patients to
prevent congenital syphilis.
The Mentor's Analysis: Antimicrobial stewardship during severe shortages requires triaging the
most effective drugs to the most vulnerable populations (pregnant women).
Professional/Academic Intuition: During the Bicillin shortage, non-pregnant syphilis
patients receive Doxycycline.
Q9: A 28-year-old MSM patient reports a recent chlamydia infection. Based on 2024-2026 CDC
guidelines, which intervention reduces future bacterial STI incidence? A) Pre-exposure
prophylaxis with daily Azithromycin B) Doxycycline 200 mg taken within 72 hours of condomless
sex C) Bicillin L-A 2.4 million units monthly D) Expedited partner therapy exclusively
● The Answer: B (Doxycycline 200 mg taken within 72 hours of condomless sex)
● Distractor Analysis:
BANK: WOMEN’S HEALTH
PRIMARY CARE (5TH ED.)
PART 0: THE NAVIGATOR
● Tier 1 (Questions 1–28): Foundational Syntax & Application. Testing "Hard Deck"
definitions, core formulas, and primary theories (e.g., HRSA 2026 guidelines,
PALM-COEIN criteria, PREVENT equation thresholds).
● Tier 2 (Questions 29–58): Complex Application & Simulation. "Situation X occurs.
Variable Y changes. What is the MOST LOGICAL outcome or immediate action?" (e.g.,
protocol pivots during Bicillin shortages, mid-course HRT adjustments).
● Tier 3 (Questions 59–88): Grandmaster Synthesis. Paragraph-long, high-stakes
scenarios requiring the synthesis of multiple, competing concepts (e.g., managing AUB in
anticoagulated patients, treating STIs in gravid populations).
PART I: THE PRIMER
This document forges elite clinical practitioners by replacing rote memorization with surgical
diagnostic precision. Mastering this specific test bank translates directly to superior patient
outcomes, diagnostic accuracy, and total command of current global women's health protocols,
ensuring high-level clinical and analytical competence.
● The PALM-COEIN Axiom: Always separate structural (PALM: Polyp, Adenomyosis,
Leiomyoma, Malignancy) from non-structural (COEIN) causes of Abnormal Uterine
Bleeding (AUB). Endometrial biopsy is absolute in women >45 or those <45 with
unopposed estrogen exposure.
● The PREVENT (2024-2026) Axiom: Cardiovascular risk assessment now encompasses
ages 30-79, removes race, adds Heart Failure (HF) to ASCVD, incorporates eGFR/BMI,
and utilizes a 7.5% 10-year risk threshold for initiating statins or antihypertensives.
● The Cervical Cancer (HRSA 2026) Axiom: Patient self-collection for primary hrHPV
testing is now an approved standard for average-risk women aged 30–65 (every 5 years).
Co-testing is explicitly forbidden under age 30.
● The Antimicrobial Stewardship Axiom: During the 2025/2026 Bicillin L-A shortage,
imported Lentocilin or remaining Bicillin is reserved strictly for pregnant patients with
syphilis; non-pregnant adults default to Doxycycline.
● The Menopause (NAMS 2025) Axiom: Hormone Therapy (HT) does not need to be
routinely discontinued at age 65. Prescribe FDA-approved formulations based on
individualized VMS/GSM symptom burden and strictly avoid compounded bioidentical
hormones.
,Guideline Entity 2025/2026 Key Update Clinical Application Source
/ Threshold Focus
AHA/ACC PREVENT Equations Threshold for primary
intervention lowered to
7.5% 10-year CVD risk.
HRSA/USPSTF Cervical Screening Approves self-collected
vaginal samples for
hrHPV in women
30-65.
CDC Doxy-PEP 200mg doxycycline
within 72 hours for
high-risk STI
prevention.
ACOG Fetal Monitoring No routine oxygen for
Category II/III if mother
is normoxic.
USPSTF Breast Screening Biennial mammography
required starting at age
40, up to age 74.
PART II: THE ELITE TEST BANK
Q1: A 32-year-old average-risk patient requests cervical cancer screening. Based on the 2026
HRSA Women's Preventive Services Guidelines, which action is the FIRST line
recommendation? A) Perform cytology alone, as she is under age 35 B) Offer patient-collected
primary hrHPV testing C) Perform concurrent cytology and pelvic ultrasound D) Defer screening
until age 35 if prior cytology was normal
● The Answer: B (Offer patient-collected primary hrHPV testing)
● Distractor Analysis:
○ A is incorrect: Cytology alone is reserved for ages 21–29; at 32, hrHPV testing is
preferred.
○ C is incorrect: Ultrasound is not a screening modality for cervical cancer.
○ D is incorrect: Screening intervals are 3 years (cytology) or 5 years (hrHPV);
deferring to 35 violates the 5-year interval.
The Mentor's Analysis: HRSA 2026 protocols authorize self-collected hrHPV testing for women
30–65, fundamentally shifting primary care workflows to empower patient autonomy.
Professional/Academic Intuition: Empower 30-65-year-old patients with hrHPV
self-collection to maximize screening compliance.
Q2: A 24-year-old patient presents for an annual exam. Based on the HRSA 2026 Guidelines,
which cervical screening strategy is MOST APPROPRIATE? A) Co-testing (Cytology + hrHPV)
B) Primary hrHPV testing C) Cervical cytology alone D) Patient-collected hrHPV swab
● The Answer: C (Cervical cytology alone)
● Distractor Analysis:
○ A is incorrect: Co-testing is explicitly not recommended for women under 30.
○ B is incorrect: Primary hrHPV is reserved for women 30 and older.
○ D is incorrect: Self-collection applies only to the hrHPV test, which is
contraindicated for her age bracket.
The Mentor's Analysis: High-risk HPV infections are highly prevalent but transient in women
under 30. Testing for HPV in this cohort leads to unnecessary colposcopies.
,Professional/Academic Intuition: Never order HPV co-testing for a patient under 30 years
old.
Q3: A 47-year-old female presents with heavy menstrual bleeding. Based on the PALM-COEIN
framework, what is the IMMEDIATELY required diagnostic step? A) Prescribe a levonorgestrel
IUD B) Order an endometrial biopsy C) Measure endometrial thickness via ultrasound D) Initiate
a GnRH antagonist
● The Answer: B (Order an endometrial biopsy)
● Distractor Analysis:
○ A is incorrect: While the LNG-IUD treats AUB, ruling out malignancy is mandatory
first.
○ C is incorrect: Ultrasound thickness cannot reliably rule out malignancy in
premenopausal women.
○ D is incorrect: GnRH antagonists treat fibroids (AUB-L), but the "M" (Malignancy)
must be evaluated first.
The Mentor's Analysis: Age >45 with AUB mandates an automatic rule-out of endometrial
hyperplasia/malignancy per ACOG 2012 and NICE 2018 guidelines. Professional/Academic
Intuition: In AUB, tissue is the issue; biopsy anyone over 45 before initiating suppression.
Q4: A 31-year-old with a BMI of 36 and a history of PCOS reports irregular, heavy menses.
Based on AUB guidelines, what is the MOST ACCURATE initial action? A) Endometrial biopsy
B) Reassurance and weight loss counseling C) Transvaginal ultrasound to measure stripe
thickness D) Immediate hysterectomy
● The Answer: A (Endometrial biopsy)
● Distractor Analysis:
○ B is incorrect: Fails to address the immediate risk of endometrial hyperplasia
caused by unopposed estrogen.
○ C is incorrect: Ultrasound is not the primary diagnostic tool to rule out cancer in
anovulatory AUB.
○ D is incorrect: Hysterectomy is a radical endpoint, not an initial diagnostic step.
The Mentor's Analysis: Women <45 with unopposed estrogen exposure (PCOS, obesity) are at
high risk for endometrial cancer and bypass the standard age threshold for biopsy.
Professional/Academic Intuition: Unopposed estrogen environments demand an
endometrial biopsy regardless of the patient's age.
Q5: A 66-year-old woman requests cardiovascular risk assessment. Based on the 2024-2026
AHA PREVENT equations, which variable is EXPLICITLY excluded from the calculation? A)
Estimated Glomerular Filtration Rate (eGFR) B) Body Mass Index (BMI) C) Patient Race D)
Heart Failure risk
● The Answer: C (Patient Race)
● Distractor Analysis:
○ A is incorrect: eGFR is a newly integrated core variable in the CKM framework.
○ B is incorrect: BMI is now included in the base PREVENT model.
○ D is incorrect: Heart Failure (HF) is now predicted alongside ASCVD to calculate
total CVD.
The Mentor's Analysis: The AHA removed race to treat it as a social, rather than biological,
construct, while adding renal and metabolic metrics. Professional/Academic Intuition: Use the
PREVENT equations to evaluate Cardiovascular-Kidney-Metabolic (CKM) syndrome
holistically, ignoring race.
Q6: A 35-year-old male-to-female (MTF) transgender patient requests routine primary care.
Based on WPATH SOC8, which screening is MOST APPROPRIATE if the patient has not
, undergone gender-affirming surgery? A) Discontinue all prostate screenings permanently B)
Defer breast cancer screening until age 65 C) Routine prostate screening based on native
anatomical guidelines D) Routine cervical cytology
● The Answer: C (Routine prostate screening based on native anatomical guidelines)
● Distractor Analysis:
○ A is incorrect: The prostate is retained during standard vaginoplasty and remains at
risk.
○ B is incorrect: Estrogen exposure alters breast cancer risk; standard screening
protocols apply based on duration of hormone use.
○ D is incorrect: MTF patients do not possess a cervix.
The Mentor's Analysis: Gender-affirming care requires screening the anatomy present,
regardless of the patient's gender identity. Professional/Academic Intuition: Screen the organs
that are physically present; anatomy dictates preventative care protocols.
Q7: A 65-year-old female undergoes a DXA scan yielding a T-score of -2.6 at the femoral neck.
Based on ACP/ACOG 2025 guidelines, which is the FIRST-line pharmacologic intervention? A)
Denosumab B) Oral Bisphosphonates C) Teriparatide D) Estrogen replacement therapy
● The Answer: B (Oral Bisphosphonates)
● Distractor Analysis:
○ A is incorrect: Denosumab was shifted to second-line due to rebound fracture risks
upon discontinuation.
○ C is incorrect: Anabolic agents are reserved for very high-risk patients with severe,
existing fractures.
○ D is incorrect: Estrogen prevents bone loss but is not first-line treatment for
diagnosed osteoporosis.
The Mentor's Analysis: Bisphosphonates remain the anchor of osteoporosis management due
to proven fracture protection, safety, and lack of rebound effect. Professional/Academic Intuition:
All standard osteoporosis treatment pathways begin with bisphosphonates.
Q8: A 24-year-old non-pregnant female is diagnosed with primary syphilis during the 2026
Bicillin L-A shortage. Based on CDC protocols, which action is MOST ACCURATE? A)
Administer IV Ceftriaxone immediately B) Utilize imported Lentocilin C) Prescribe Doxycycline
100 mg orally twice daily for 14 days D) Prioritize the remaining clinic stock of Bicillin L-A for her
● The Answer: C (Prescribe Doxycycline 100 mg orally twice daily for 14 days)
● Distractor Analysis:
○ A is incorrect: Ceftriaxone is second-line and not the preferred alternative for
primary syphilis.
○ B is incorrect: Lentocilin (import) is strictly prioritized for pregnant patients.
○ D is incorrect: Bicillin stocks must be hoarded exclusively for pregnant patients to
prevent congenital syphilis.
The Mentor's Analysis: Antimicrobial stewardship during severe shortages requires triaging the
most effective drugs to the most vulnerable populations (pregnant women).
Professional/Academic Intuition: During the Bicillin shortage, non-pregnant syphilis
patients receive Doxycycline.
Q9: A 28-year-old MSM patient reports a recent chlamydia infection. Based on 2024-2026 CDC
guidelines, which intervention reduces future bacterial STI incidence? A) Pre-exposure
prophylaxis with daily Azithromycin B) Doxycycline 200 mg taken within 72 hours of condomless
sex C) Bicillin L-A 2.4 million units monthly D) Expedited partner therapy exclusively
● The Answer: B (Doxycycline 200 mg taken within 72 hours of condomless sex)
● Distractor Analysis:
